The global multiple sclerosis drugs market was valued at USD 22.3 Billion in 2025 and is projected to reach USD 39.7 Billion by the end of 2036, expanding at a CAGR of 5.4% from 2026 to 2036. Market growth is driven by the rising prevalence of multiple sclerosis worldwide, advancements in disease-modifying therapies, increasing adoption of oral and high-efficacy treatments, and growing demand...